Anzeige
❌
Mehr »
Donnerstag, 22.10.2026 - Börsentäglich über 12.000 News
URAN: JETZT WIRD ES SPANNEND
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
SS

WKN: A3EYA0 | ISIN: US86272A3059 | Ticker-Symbol: E2O
Lang & Schwarz
22.10.26 | 07:00
2,050 Euro
-100,00 % -2,050
1-Jahres-Chart
STRATA SKIN SCIENCES INC Chart 1 Jahr
5-Tage-Chart
STRATA SKIN SCIENCES INC 5-Tage-Chart
RealtimeGeldBriefZeit
2,0402,06007:00
GlobeNewswire (Europe)
532 Leser
Artikel bewerten:
(2)

STRATA Skin Sciences, Inc.: STRATA Skin Sciences Appoints Medical Device Commercial Leader Erica Jordan as Chief Executive Officer

HORSHAM, Pa., July 28, 2026 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. ("STRATA" or the "Company"), a global leader in excimer laser therapy dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, has appointed industry veteran Erica Jordan as Chief Executive Officer, effective July 12, 2026.

STRATA chairperson Dr. Uri Geiger stated, "Erica has a proven record of expanding and transforming sales operations in large markets. We look forward to collaborating closely with Erica as she brings STRATA into its next era and translates the historical expanded CPT Code coverage into commercial success. I also want to thank Dr. Dolev Rafaeli for his long tenure as CEO and building the foundation of Strata Skin Sciences"

Erica Jordan is a strategic commercial leader with a focus on partnering with providers to enable care and improve business practices. She is well versed in revitalizing organizations by increasing revenue, scaling operations, expanding markets, transforming sales and commercial teams, and launching innovative products and services in diverse markets. She has demonstrated a long-standing commitment to cross-functional collaboration and meaningful customer engagement, excelling in aligning teams with shared goals and navigating matrix organizations to achieve corporate objectives.

"STRATA has what many companies spend years trying to build: proven clinical outcomes, established reimbursement, and a commercial partnership model that removes the capital barrier for dermatology practices," said Ms. Jordan. "My focus will be on scaling the commercial organization so that more practices - and ultimately more patients who are candidates for these therapies - have access to them."

Prior to joining STRATA, Ms. Jordan served as Chief Commercial Officer for Revance Therapeutics, spearheading sales, marketing (B2B and B2C), operations, corporate communications, investor relations, corporate strategy, and business excellence in domestic and international markets. Prior, she served as Metrex president at Envista Holdings (former Danaher Company). She has held leadership positions within the sales and marketing functions at leading organizations, including Change Healthcare (now part of Optum), Philips Healthcare, Fujifilm Medical, Siemens Medical Solutions, and GE Healthcare. She holds a Bachelor of Science degree in Marketing from the University of Wisconsin- Milwaukee.

About STRATA Skin Sciences, Inc.

STRATA Skin Sciences is a medical technology company dedicated to developing, commercializing, and marketing innovative products for the in-office treatment of various dermatologic conditions, such as psoriasis, vitiligo, and acne. Its products include the XTRAC excimer laser, VTRAC lamp systems, and the TheraClearX Acne Therapy System. STRATA is proud to offer these exciting technologies in the U.S. through its unique Partnership Program. STRATA's popular partnership approach includes a fee per treatment cost structure versus an equipment purchase, installation and use of the device, on-site training for practice personnel, service and maintenance of the equipment, dedicated account and customer service associates, and co-op advertising support to help raise awareness and promote the program within the practice.

Safe Harbor

This press release includes "forward-looking statements" within the meaning of the Securities Litigation Reform Act of 1995. These statements involve known and unknown risks and uncertainties that may cause actual results to differ materially from those expressed or implied by such statements. STRATA Skin Sciences undertakes no obligation to publicly update or revise any forward-looking statements.

Contact

STRATA Skin Sciences, Inc.

5 Walnut Grove Drive, Suite 140, Horsham, PA 19044

(215) 619-3200 | ir@strataskinsciences.com | strataskinsciences.com


© 2026 GlobeNewswire (Europe)
Historische Öl-Krise - 5 Aktien, die davon profitieren!
Der Iran-Krieg hat den globalen Energiemarkt erschüttert. Zerstörte Förderanlagen, ausgefallene Transportwege und fehlende Raffineriekapazitäten sorgen dafür, dass nicht nur Rohöl, sondern vor allem Benzin und Diesel knapp und teuer bleiben könnten. Selbst ein Ende der Kämpfe würde das Problem nicht über Nacht lösen, der Wiederaufbau der Energieinfrastruktur dürfte Jahre dauern.

Während viele Anleger jetzt auf ExxonMobil, Chevron oder Shell setzen, könnte das größere Potenzial längst woanders liegen. Denn hohe Ölpreise machen neue Investitionen in Förderung, Transport und Verarbeitung wieder attraktiv. Davon profitieren vor allem jene Unternehmen, die Bohrtechnik, Ausrüstung und Dienstleistungen bereitstellen oder bereits über wertvolle Infrastruktur verfügen.

Hier dürfte die zweite Welle des Öl-Booms entstehen. Statt den bereits stark gelaufenen Produzenten hinterherzulaufen, können Anleger auf die Unternehmen setzen, die am milliardenschweren Wiederaufbau der globalen Energieinfrastruktur verdienen.

In unserem aktuellen Spezialreport zeigen wir 5 Aktien, die von der historischen Öl-Krise besonders profitieren könnten.

Jetzt den kostenlosen Report sichern und die möglichen Gewinner der zweiten Öl-Welle entdecken!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.